骨质疏松症的共病研究与早期筛查

doi:10.12114/j.issn.1007-9572.2022.0425

中国全科医学 ›› 2022, Vol. 25 ›› Issue (35): 4369-4374.DOI: 10.12114/j.issn.1007-9572.2022.0425

所属专题：骨健康最新文章合辑；共病最新文章合辑；骨质疏松最新文章合辑

骨质疏松症的共病研究与早期筛查

魏戌¹^,², 刘宁¹, 章轶立³, 韩涛¹, 孙凯¹^,², 齐保玉¹, 陈忻¹^,², 秦晓宽¹, 高景华¹^,², 谢雁鸣⁴^,^*(), 朱立国¹^,²^,^*()

¹100102　北京市，中国中医科学院望京医院
²100700　北京市中西医结合骨伤研究所
³210023　江苏省南京市，南京中医药大学中医学院·中西医结合学院
⁴100700　北京市，中国中医科学院中医临床基础医学研究所

收稿日期:2022-05-15 修回日期:2022-07-12 出版日期:2022-12-15 发布日期:2022-08-04
通讯作者: 谢雁鸣, 朱立国
魏戌，刘宁，章轶立，等.骨质疏松症的共病研究与早期筛查[J].中国全科医学，2022，25（35）：4369-4374.[www.chinagp.net]
作者贡献：魏戌、谢雁鸣、朱立国进行文章的整体构思与设计；魏戌、刘宁、章轶立进行文献收集、整理，完成论文撰写；韩涛、孙凯、齐保玉、陈忻、秦晓宽进行文章的修订；高景华、谢雁鸣、朱立国负责文章的质量控制及审校，对文章整体负责与监督管理。
基金资助:
国家中医药管理局传承创新团队项目(ZYYCTXD-C-202003); 中国中医科学院科技创新工程重大攻关项目(CI2021A02013); 中国中医科学院循证医学中心业务研究室主任专项(2020YJSZX-4); 中国中医科学院优秀青年科技人才（创新类）培养专项(ZZ13-YQ-039)

Comorbidities of Osteoporosis: Recent Advances and Early Screening

WEI Xu¹^,², LIU Ning¹, ZHANG Yili³, HAN Tao¹, SUN Kai¹^,², QI Baoyu¹, CHEN Xin¹^,², QIN Xiaokuan¹, GAO Jinghua¹^,², XIE Yanming⁴^,^*(), ZHU Liguo¹^,²^,^*()

¹Wangjing Hospital of Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China
²Beijing Institute of Orthopaedical Traumatology of the Integrating of Traditional and Western Medicine, Beijing 100700, China
³School of Traditional Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
⁴Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

Received:2022-05-15 Revised:2022-07-12 Published:2022-12-15 Online:2022-08-04
Contact: XIE Yanming, ZHU Liguo
About author:
WEI X, LIU N, ZHANG Y L, et al. Comorbidities of osteoporosis: recent advances and early screening[J]. Chinese General Practice, 2022, 25 (35) : 4369-4374.

分享到

摘要/Abstract

摘要： 骨质疏松症患者常共患多种疾病，涉及内分泌、循环、呼吸、泌尿、免疫、骨骼肌肉、神经等多系统疾病，共病发生率较高，且这些共病可能会加重骨质疏松症，从而增加骨质疏松性骨折发生的风险，严重影响患者生活质量，同时使疾病管理更加复杂，给家庭和社会带来沉重负担。目前对于骨质疏松症共病的研究较为缺乏，现有的研究策略在共因、共防、共治方面难以有效指导临床医生开展共病管理。鉴于此，建议引入多学科综合治疗（MDT）理念，加强骨质疏松症相关共病及其致病机制的认识，对于可能合并骨质疏松症的患者需尽早筛查，一旦发现骨量减少、骨质疏松，应积极进行防治以降低骨折风险，早筛、早诊、早治，实现骨质疏松症共病的共防、共治。

关键词: 骨质疏松, 共病现象, 骨质疏松性骨折, 诊断, 发病机制, 多学科综合治疗, 早期筛查

Abstract:

Comorbidities are highly prevalent in osteoporosis patients, including endocrine, circulatory, respiratory, urinary, immune, musculoskeletal, and neurological diseases, which may aggravate osteoporosis, increase the risk of osteoporotic fracture, and seriously affect the quality of patient's life, bringing more challenges to associated clinical management, and imposing a heavy burden on the families and society. There is still a lack of studies on comorbidities of osteoporosis, and the existing research strategies are inadequate to support clinicians to carry out comorbidity management in terms of understanding the causes of osteoporosis and associated comorbidities, and delivering interventions for prevention and treatment of both of them. In view of this, it is suggested to use multidisciplinary integrated treatment, and strengthen the understanding of osteoporosis related comorbidities and their pathogenesis. Moreover, the screening for osteoporosis in people with possible osteoporosis risk should be performed as early as possible, and actions should be taken actively to reduce the risk of fracture in those who are found with osteopenia or osteoporosis. Early screening, diagnosis and treatment are necessary to realize the prevention and treatment of osteoporosis and associated comorbidities.

Key words: Osteoporosis, Comorbidity, Osteoporotic fractures, Diagnosis, Pathogenic mechanism, Multidisciplinary integrated treatment, Early screening

魏戌,刘宁,章轶立,等. 骨质疏松症的共病研究与早期筛查[J]. 中国全科医学, 2022, 25(35): 4369-4374. DOI: 10.12114/j.issn.1007-9572.2022.0425.
WEI Xu,LIU Ning,ZHANG Yili, et al. Comorbidities of Osteoporosis: Recent Advances and Early Screening[J]. Chinese General Practice, 2022, 25(35): 4369-4374. DOI: 10.12114/j.issn.1007-9572.2022.0425.

参考文献 52

[1]	FEINSTEIN A R. The pre-therapeutic classification of co-morbidity in chronic disease[J]. J Chronic Dis，1970，23（7）：455-468. DOI：10.1016/0021-9681(70)90054-8.
[2]	SALIVE M E. Multimorbidity in older adults[J]. Epidemiol Rev，2013，35：75-83. DOI：10.1093/epirev/mxs009.
[3]	SHARMA B，SINGH H，CHODHARY P，et al. Osteoporosis in otherwise healthy patients with type 2 diabetes：a prospective gender based comparative study[J]. Indian J Endocrinol Metab，2017，21（4）：535-539. DOI：10.4103/ijem.IJEM_108_17.
[4]	CORTET B，LUCAS S，LEGROUX-GEROT I，et al. Bone disorders associated with diabetes mellitus and its treatments[J]. Joint Bone Spine，2019，86（3）：315-320. DOI：10.1016/j.jbspin.2018.08.002.
[5]	GOLDSHTEIN I，NGUYEN A M，DEPAPP A E，et al. Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients[J]. Arch Osteoporos，2018，13（1）：15. DOI：10.1007/s11657-018-0432-x.
[6]	HULL B，SMITH N R. Diabetes and bone[J]. Am J Med Sci，2016，351（4）：356-360. DOI：10.1016/j.amjms.2016.02.010.
[7]	VALDERRABANO R J，LINARES M I. Diabetes mellitus and bone health：epidemiology，etiology and implications for fracture risk stratification[J]. Clin Diabetes Endocrinol，2018，4：9. DOI：10.1186/s40842-018-0060-9.
[8]	GOSWAMI R，NAIR A. Diabetes mellitus，vitamin D & osteoporosis：insights[J]. Indian J Med Res，2019，150（5）：425-428. DOI：10.4103/ijmr.IJMR_1920_19.
[9]	SCHARLA S. Diabetes mellitus and osteoporosis：who should be addressed and how to confirm the diagnosis[J]. MMW Fortschr Med，2018，160（21/22）：65-69. DOI：10.1007/s15006-018-1239-9.
[10]	YAMAMOTO M，YAMAUCHI M，SUGIMOTO T. Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus[J]. PLoS One，2019，14（9）：e0222571. DOI：10.1371/journal.pone.0222571.
[11]	GIANGREGORIO L M，LESLIE W D，LIX L M，et al. FRAX underestimates fracture risk in patients with diabetes[J]. J Bone Miner Res，2012，27（2）：301-308. DOI：10.1002/jbmr.556.
[12]	PAPAIOANNOU I，PANTAZIDOU G，KOKKALIS Z，et al. Systematic review：are the elderly with diabetes mellitus type 2 prone to fragility fractures? [J]. Cureus，2021，13（4）：e14514. DOI：10.7759/cureus.14514.
[13]	IRVING J T. Calcification of the organic matrix of enamel[J]. Arch Oral Biol，1963，8：773-774. DOI：10.1016/0003-9969(63)90010-4.
[14]	MURCH O，COLLIN M，HINDS C J，et al. Lipoproteins in inflammation and Sepsis. I. Basic science[J]. Intensive Care Med，2007，33（1）：13-24. DOI：10.1007/s00134-006-0432-y.
[15]	LEKAMWASAM S，WEERARATHNA T，RODRIGO M，et al. Osteoporosis and cardiovascular risk among premenopausal women in Sri Lanka[J]. J Clin Densitom，2009，12（2）：245-250. DOI：10.1016/j.jocd.2009.02.001.
[16]	WANG Y M，ZHU Y，LU S D，et al. Beneficial effects of paeoniflorin on osteoporosis induced by high-carbohydrate，high-fat diet-associated hyperlipidemia in vivo[J]. Biochem Biophys Res Commun，2018，498（4）：981-987. DOI：10.1016/j.bbrc.2018.03.093.
[17]	TINTUT Y，DEMER L L. Effects of bioactive lipids and lipoproteins on bone[J]. Trends Endocrinol Metab，2014，25（2）：53-59. DOI：10.1016/j.tem.2013.10.001.
[18]	蔡晓燕，董光富. 脂代谢及血清骨钙素水平与骨质疏松症的相关性分析[J]. 中国骨质疏松杂志，2016，22（6）：711-712，730. DOI：10.3969/j.issn.1006-7108.2016.06.011.
[19]	CHEN S J，LIN C S，LIN C L，et al. Osteoporosis is associated with high risk for coronary heart disease：a population-based cohort study[J]. Medicine （Baltimore），2015，94（27）：e1146. DOI：10.1097/MD.0000000000001146.
[20]	李洁，杨希立，郭晋爱，等. 老年冠心病与骨质疏松的相关性研究[J]. 中国实用内科杂志，2010，30（S1）：20-23.
[21]	LAROCHE M，PECOURNEAU V，BLAIN H，et al. Osteoporosis and ischemic cardiovascular disease[J]. Joint Bone Spine，2017，84（4）：427-432. DOI：10.1016/j.jbspin.2016.09.022.
[22]	魏戌，章轶立，谢雁鸣，等. 骨质疏松症与冠心病共病患者的临床特征及其影响因素[J]. 中华骨质疏松和骨矿盐疾病杂志，2020，13（4）：318-325. DOI：10.3969/j.issn.1674-2591.2020.04.006.
[23]	BROUSSARD D L，MAGNUS J H. Coronary heart disease risk and bone mineral density among US women and men[J]. J Womens Health （Larchmt），2008，17（3）：479-490. DOI：10.1089/jwh.2007.0593.
[24]	PACCOU J，EDWARDS M H，WARD K，et al. Relationships between bone geometry，volumetric bone mineral density and bone microarchitecture of the distal radius and Tibia with alcohol consumption[J]. Bone，2015，78：122-129. DOI：10.1016/j.bone.2015.05.002.
[25]	YANG S，NGUYEN N D，CENTER J R，et al. Association between hypertension and fragility fracture：a longitudinal study[J]. Osteoporos Int，2014，25（1）：97-103. DOI：10.1007/s00198-013-2457-8.
[26]	AL-HARIRI M，ALDHAFERY B. Association of hypertension and lipid profile with osteoporosis[J]. Scientifica （Cairo），2020，2020：7075815. DOI：10.1155/2020/7075815.
[27]	VARENNA M，MANARA M，GALLI L，et al. The association between osteoporosis and hypertension：the role of a low dairy intake[J]. Calcif Tissue Int，2013，93（1）：86-92. DOI：10.1007/s00223-013-9731-9.
[28]	HU X L，SUN Y C，XU W H，et al. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD[J]. Respirology，2017，22（1）：126-132. DOI：10.1111/resp.12878.
[29]	WATANABE R，TAI N，HIRANO J，et al. Independent association of bone mineral density and trabecular bone score to vertebral fracture in male subjects with chronic obstructive pulmonary disease[J]. Osteoporos Int，2018，29（3）：615-623. DOI：10.1007/s00198-017-4314-7.
[30]	INOUE D，WATANABE R，OKAZAKI R. COPD and osteoporosis：links，risks，and treatment challenges[J]. Int J Chron Obstruct Pulmon Dis，2016，11：637-648. DOI：10.2147/COPD.S79638.
[31]	OZCAKIR S，SIGIRLI D，URSAVAS A，et al. COPD and osteoporosis：associated factors in patients treated with inhaled corticosteroids[J]. Int J Chron Obstruct Pulmon Dis，2020，15：2441-2448. DOI：10.2147/COPD.S274728.
[32]	BARNES P J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol，2016，138（1）：16-27. DOI：10.1016/j.jaci.2016.05.011.
[33]	ROMME E A，GEUSENS P，LEMS W F，et al. Fracture prevention in COPD patients；a clinical 5-step approach[J]. Respir Res，2015，16：32. DOI：10.1186/s12931-015-0192-8.
[34]	KINSELLA S，CHAVRIMOOTOO S，MOLLOY M G，et al. Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis[J]. Nephron Clin Pract，2010，116（3）：c256-262. DOI：10.1159/000317207.
[35]	NITTA K，YAJIMA A，TSUCHIYA K. Management of osteoporosis in chronic kidney disease[J]. Intern Med，2017，56（24）：3271-3276. DOI：10.2169/internalmedicine.8618-16.
[36]	HSU C Y，CHEN L R，CHEN K H. Osteoporosis in patients with chronic kidney diseases：a systemic review[J]. Int J Mol Sci，2020，21（18）：6846. DOI：10.3390/ijms21186846.
[37]	MAZZAFERRO S，DE MARTINI N，ROTONDI S，et al. Bone，inflammation and chronic kidney disease[J]. Clin Chim Acta，2020，506：236-240. DOI：10.1016/j.cca.2020.03.040.
[38]	KETTELER M，BLOCK G A，EVENEPOEL P，et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder （CKD-MBD） Guideline Update：what's changed and why it matters[J]. Kidney Int，2017，92（6）：1558. DOI：10.1016/j.kint.2017.10.001.
[39]	LIU L C，LU M C，WANG S Y，et al. Association of use of rehabilitation services with development of osteoporosis among patients with rheumatoid arthritis：a nationwide population-based cohort study[J]. Osteoporos Int，2018，29（8）：1897-1903. DOI：10.1007/s00198-018-4569-7.
[40]	LINDNER L，CALLHOFF J，ALTEN R，et al. Osteoporosis in patients with rheumatoid arthritis：trends in the German National Database 2007-2017[J]. Rheumatol Int，2020，40（12）：2005-2012. DOI：10.1007/s00296-020-04593-6.
[41]	ADAMI G，SAAG K G. Osteoporosis pathophysiology，epidemiology，and screening in rheumatoid arthritis[J]. Curr Rheumatol Rep，2019，21（7）：34. DOI：10.1007/s11926-019-0836-7.
[42]	LLORENTE I，GARCÍA-CASTAÑEDA N，VALERO C，et al. Osteoporosis in rheumatoid arthritis：dangerous liaisons[J]. Front Med （Lausanne），2020，7：601618. DOI：10.3389/fmed.2020.601618.
[43]	SIMON D，KLEYER A，ENGLBRECHT M，et al. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints，the gut and the skin[J]. Bone，2018，116：87-93. DOI：10.1016/j.bone.2018.07.017.
[44]	FARDELLONE P，SALAWATI E，LE MONNIER L，et al. Bone loss，osteoporosis，and fractures in patients with rheumatoid arthritis：a review[J]. J Clin Med，2020，9（10）：E3361. DOI：10.3390/jcm9103361.
[45]	AL SALEH J，SAYED M E，MONSEF N，et al. The prevalence and the determinants of musculoskeletal diseases in emiratis attending primary health care clinics in Dubai[J]. Oman Med J，2016，31（2）：117-123. DOI：10.5001/omj.2016.23.
[46]	CLAYTON E S，HOCHBERG M C. Osteoporosis and osteoarthritis，rheumatoid arthritis and spondylarthropathies[J]. Curr Osteoporos Rep，2013，11（4）：257-262. DOI：10.1007/s11914-013-0172-1.
[47]	VRTACNIK P，ZUPAN J，MLAKAR V，et al. Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis[J]. Sci Rep，2018，8（1）：16215. DOI：10.1038/s41598-018-34255-4.
[48]	GANGULY P，EL-JAWHARI J J，GIANNOUDIS P V，et al. Age-related changes in bone marrow mesenchymal stromal cells：a potential impact on osteoporosis and osteoarthritis development[J]. Cell Transplant，2017，26（9）：1520-1529. DOI：10.1177/0963689717721201.
[49]	曾展鹏，戴才锋，郑伟杰，等. 超声骨密度筛查膝关节骨性关节炎患者骨质疏松症的效果[J]. 实用医学杂志，2018，34（2）：243-246. DOI：10.3969/j.issn.1006-5725.2018.02.021.
[50]	CHENG B H，CHEN P C，YANG Y H，et al. Effects of depression and antidepressant medications on hip fracture：a population-based cohort study in Taiwan[J]. Medicine （Baltimore），2016，95（36）：e4655. DOI：10.1097/MD.0000000000004655.
[51]	WENG S F，HSU H R，WENG Y L，et al. Health-related quality of life and medical resource use in patients with osteoporosis and depression：a cross-sectional analysis from the national health and nutrition examination survey[J]. Int J Environ Res Public Health，2020，17（3）：E1124. DOI：10.3390/ijerph17031124.
[52]	ROSENBLAT J D，GREGORY J M，CARVALHO A F，et al. Depression and disturbed bone metabolism：a narrative review of the epidemiological findings and postulated mechanisms[J]. Curr Mol Med，2016，16（2）：165-178. DOI：10.2174/1566524016666160126144303.

骨质疏松症的共病研究与早期筛查

Comorbidities of Osteoporosis: Recent Advances and Early Screening

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 52

相关文章 15

编辑推荐

Metrics

留言

[1]	周启保, 罗潇, 陈玲, 曹俊达, 李菊香, 徐劲松, 苏海. 收缩压昼夜变异率联合正常RR间期标准差对冠心病诊断价值的临床研究[J]. 中国全科医学, 2025, 28(30): 3760-3765.
[2]	王婷婷, 唐勇, 张文轲, 李志刚. 高尿酸血症运动干预的研究进展[J]. 中国全科医学, 2025, 28(30): 3841-3846.
[3]	李淏, 李沛瑾, 刘婷婷, 崔译元, 李思聪, 刘丽星, 冯利, 癌性疼痛中西医结合诊疗指南工作组. 癌性疼痛中西医结合诊疗指南[J]. 中国全科医学, 2025, 28(30): 3729-3740.
[4]	周晟, 邓长生, 邹冠炀, 宋健平. 疟疾心血管疾病并发症发病机制的研究进展[J]. 中国全科医学, 2025, 28(27): 3466-3472.
[5]	智从从, 李雪, 程一乘, 王孝龙, 郑丽华. 痔中西医结合诊疗指南（2025版）[J]. 中国全科医学, 2025, 28(26): 3217-3228.
[6]	中国老年医学学会, 浙江省医学会全科医学分会, 全科未分化疾病专家协作组. 消瘦诊治与管理专家共识（2025）[J]. 中国全科医学, 2025, 28(21): 2577-2594.
[7]	熊鑫, 李洋, 石峰, 杨连, 段维, 陈蓓, 李勇, 赵林伟, 付泉水, 范小萍, 杨国庆. 基于人工智能的胸腰椎骨密度测定系统及其校准研究[J]. 中国全科医学, 2025, 28(19): 2398-2406.
[8]	邓雅倩, 曹春莉, 马金梅, 李文肖, 徐泽林, 成静, 李军. S-Detect联合声触诊组织成像定量技术对乳腺癌腋窝淋巴结转移的预测价值研究[J]. 中国全科医学, 2025, 28(17): 2149-2155.
[9]	谭文彬, 李佳, 刘明玉, 路永欣, 程雅欣. 神经系统疾病及相关治疗药物对骨质疏松症影响的研究进展[J]. 中国全科医学, 2025, 28(17): 2092-2100.
[10]	贺婷, 李佳, 谭文彬. 循环系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2101-2112.
[11]	陈钡钡, 李佳, 谭文彬. 内分泌代谢系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2082-2091.
[12]	李佳, 谭文彬. 继发性骨质疏松症防治困境与对策探究[J]. 中国全科医学, 2025, 28(17): 2075-2081.
[13]	顾洁, 黄延焱. 罕见病诊治及全过程管理：全科医生的作用不可或缺[J]. 中国全科医学, 2025, 28(16): 1955-1960.
[14]	孙清, 吴玉霄, 崔立敏. 中国2型糖尿病患者肌少-骨质疏松症患病率的Meta分析[J]. 中国全科医学, 2025, 28(12): 1520-1526.
[15]	王宇新, 彭文婉, 周正, 黄海阳, 卢晓敏, 董明国. 胃癌前状态的癌变风险及其发病机制的研究进展[J]. 中国全科医学, 2025, 28(11): 1411-1416.